ROIV · Roivant Sciences Ltd.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q1 FY27 earnings call · Aug 6, 2026TL;DR. Roivant reported Q1 FY2026 results with $3.9B in cash (excluding the $950M Moderna settlement payment received in July), received the initial Moderna settlement funds, advanced brepocitinib toward a potential DM launch by end of September 2026 and initiated a Phase 3 in cutaneous sarcoidosis, and remains on track for multiple second-half 2026 readouts (NIU, PH-ILD, CLE).
- + Received initial $950M payment from Moderna settlement, with up to $1.3B more contingent on appeal
- + First patients enrolled in Phase 3 brepocitinib study in cutaneous sarcoidosis, with Phase 2 showing 77% vs 0% on the primary endpoint
- + Cash position of $3.9B supports runway into profitability
- + Lichen planopilaris Phase 2b/3 enrollment is progressing well for brepocitinib's fourth prep signal indication
- − GAAP net loss widened to $290.6M from $273.9M year-over-year
- − R&D expenses rose $49.1M YoY to $202.0M driven by anti-FcRn franchise and mosliciguat program costs
- − G&A expenses increased $31.5M YoY to $165.5M, including $18.8M in Moderna-related employee bonuses
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ROIV
this stock
Roivant Sciences Ltd.
|
$25.86B | +68.5% | -71.6% | — | 5.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ROIV | -0.7% | +5.9% | +28.4% | +5.6% | +68.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | 0.0% | +5.8% | +16.2% | +6.2% | +56.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.